Home

JONATHAN SILVERSTEIN

CIK 1171005 · last filed 2020-10-06

JONATHAN SILVERSTEIN is a corporate insider who has filed 49 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing shows the insider bought $12.4M of ARQT on Oct 6, 2020. Across all open-market trades the lifetime net is −$235.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $350.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$350.57M

Companies

12

Total Filings

49

Lifetime Open-Market Net

-$235.88M

Filer Profile

Reported Address
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARQT Director 4,267,564 $26.89 $114.75M $21.90M 3 2020-10-06
Adicet Bio, Inc. (TORC) Delisted Director 613,865 — — $8.00M 3 2020-06-05
AVEDRO INC (AVDR) Delisted Director 0 $24.25 $0 $0 3 2019-11-25
GKOS Director 66,790 $155.22 $10.37M -$104.42M 11 2018-03-06
scPharmaceuticals Inc. (SCPH) Delisted Director 2,576,532 $5.67 $14.61M $0 1 2017-11-21
Roka BioScience, Inc. (ROKA) Delisted Director 227,307 — — $4.60M 4 2016-09-23
BOLD Director 4,435,538 $2.66 $11.80M $500.0K 2 2016-08-25
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Director 1,121,583 $19.00 $21.31M -$174.29M 16 2015-11-27
Relypsa Inc (RLYP) Delisted Director 3,810,642 — — $7.83M 1 2013-11-20
NxStage Medical, Inc. (NXTM) Delisted Director — — — $0 3 2010-05-28
PODD Director 1,568,841 $136.18 $213.64M $0 1 2007-05-18
AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted Director 2,374,190 — — $0 1 2007-03-05

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-10-06 ARQT Buy (P) +496,000 $12.40M EDGAR
2020-06-05 Adicet Bio, Inc. (TORC) Delisted Grant (A) — $0 EDGAR
2020-03-03 ARQT Grant (A) — $0 EDGAR
2020-02-04 ARQT Mixed +4,673,850 $9.50M EDGAR
2019-11-25 AVEDRO INC (AVDR) Delisted Disp (D) −4,240,128 $0 EDGAR
2019-06-18 AVEDRO INC (AVDR) Delisted Grant (A) — $0 EDGAR
2019-05-09 Adicet Bio, Inc. (TORC) Delisted Grant (A) — $0 EDGAR
2019-02-19 AVEDRO INC (AVDR) Delisted Mixed +4,087,710 $0 EDGAR
2018-03-06 GKOS Sell (S) −836,500 -$26.79M EDGAR
2018-01-30 Adicet Bio, Inc. (TORC) Delisted Mixed +4,830,387 $8.00M EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.